<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">nefr</journal-id><journal-title-group><journal-title xml:lang="ru">Нефрология</journal-title><trans-title-group xml:lang="en"><trans-title>Nephrology (Saint-Petersburg)</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">1561-6274</issn><issn pub-type="epub">2541-9439</issn><publisher><publisher-name>Pavlov First Saint-Petersburg State Medical University</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.36485/1561-6274-2021-25-5-92-98</article-id><article-id custom-type="elpub" pub-id-type="custom">nefr-2026</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>ОРИГИНАЛЬНЫЕ СТАТЬИ. КЛИНИЧЕСКИЕ ИССЛЕДОВАНИЯ</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>ORIGINAL ARTICLES. CLINICAL INVESTIGATIONS</subject></subj-group></article-categories><title-group><article-title>Роль МСР-1 в развитии тубулоинтерстициального фиброза у пациентов с первичными хроническими гломерулонефритами</article-title><trans-title-group xml:lang="en"><trans-title>Role of MCP-1 in the development of tubulointerstitial fibrosis in patients with primary chronic glomerulonephritis</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-6367-6727</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Мухтарова</surname><given-names>А. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Mukhtarova</surname><given-names>A. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Мухтарова Айтан Валик кызы, кафедра внутренних болезней №2</p><p>344022, г. Ростов-на-Дону, пер. Нахичеванский д. 29</p><p>Тел.: 8(908)510-81-51</p></bio><bio xml:lang="en"><p>Aytan V. Mukhtarova, MD, Department of Internal Medicine№2</p><p>344022, Rostov-on-Don, Nakhichevansky av., 29</p><p>Tel.: 8 (908)510-81-51</p></bio><email xlink:type="simple">ayka.mukhtarova@gmail.com</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-5329-7050</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Батюшин</surname><given-names>М. М.</given-names></name><name name-style="western" xml:lang="en"><surname>Batyushin</surname><given-names>M. M.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Проф. Батюшин Михаил Михайлович, д-р мед. наук, кафедра внутренних болезней №2; Нефрологическое отделение</p><p>344111, г. Ростов-на-Дону, пер. Нахичеванский, д. 29</p><p>Teл.: 8 (918) 501-88-01</p></bio><bio xml:lang="en"><p>Prof. Mikhail M. Batyushin, MD, PhD, DMedSci, Department of Internal Medicine №2; Nephrology Department</p><p>344022, Rostov-on-Don, Nakhichevansky av., 29</p><p>Tel.: 8 (918) 501-88-01,</p></bio><email xlink:type="simple">batjushin-m@rambler.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-2201-5065</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Синельник</surname><given-names>Е. С.</given-names></name><name name-style="western" xml:lang="en"><surname>Sinelnik</surname><given-names>Е. А.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Синельник Елена Александровна, патологоанатомическое отделение, зав. отделением</p><p>344022, г. Ростов-на-Дону, ул. 1-й Конной Армии, д. 3</p><p>Тел.: 8(863)252-19-30</p></bio><bio xml:lang="en"><p>Elena A. Sinelnik, MD, pathological department</p><p>344022, Rostov-on-Don, str. Of 1st Konnoy Army, 3</p><p>Tel .: 8 (863) 252-19-30</p></bio><email xlink:type="simple">ob2p@mail.ru</email><xref ref-type="aff" rid="aff-2"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-4736-9708</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Антипова</surname><given-names>Н. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Antipova</surname><given-names>N. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Антипова Наталья Витальевна, нефрологическое отделение</p><p>344022, г. Ростов-на-Дону, ул. 1-й Конной Армии, д. 3</p><p>Тел.: 8(863)252-19-30</p></bio><bio xml:lang="en"><p>Natalia V. Antipova,MD, nephrology department</p><p>344022, Rostov-on-Don, str. Of 1st Konnoy Army, 3</p><p>Tel.: 8 (863) 310-55-30</p></bio><email xlink:type="simple">ob2p@mail.ru</email><xref ref-type="aff" rid="aff-2"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>Ростовский государственный медицинский университет</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Rostov State Medical University</institution><country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-2"><aff xml:lang="ru"><institution>Государственное бюджетное учреждение «Областная клиническая больница №2»</institution><country>Россия</country></aff><aff xml:lang="en"><institution>State budgetary institution "Regional Clinical Hospital №2"</institution><country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2021</year></pub-date><pub-date pub-type="epub"><day>02</day><month>09</month><year>2021</year></pub-date><volume>25</volume><issue>5</issue><fpage>92</fpage><lpage>98</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Мухтарова А.В., Батюшин М.М., Синельник Е.С., Антипова Н.В., 2021</copyright-statement><copyright-year>2021</copyright-year><copyright-holder xml:lang="ru">Мухтарова А.В., Батюшин М.М., Синельник Е.С., Антипова Н.В.</copyright-holder><copyright-holder xml:lang="en">Mukhtarova A.V., Batyushin M.M., Sinelnik Е.А., Antipova N.V.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://journal.nephrolog.ru/jour/article/view/2026">https://journal.nephrolog.ru/jour/article/view/2026</self-uri><abstract><p>ВВЕДЕНИЕ. На сегодняшний день изучение факторов, участвующих в клубочково-канальцевых патологических связях, приводящих к повреждению тубулоинтерстициальной ткани, является одним из актуальных направлений нефрологии.ЦЕЛЬ: изучение влияния МСР-1 в развитии тубулоинтерстициального фиброза как фактора необратимого прогрессирования хронической почечной недостаточности. ПАЦИЕНТЫ И МЕТОДЫ. В исследовании приняли участие 75 пациентов с первичными хроническими гломерулонефритами. РЕЗУЛЬТАТЫ. Средний возраст больных составил 36,7±12,3 года, из них лиц мужского пола – 52, женщин – 23. Средний стаж нефрологического заболевания – 3,0 [1,0;5,0] года. В общей популяции умеренная степень экспрессии МСР-1, оцениваемая в 2 балла, составила 35 %, выраженная экспрессия выявлена у 25 % респондентов. В мезангии клубочков и макрофагах выраженная степень экспрессии МСР-1 составила 20 и 16 % соответственно, что характеризует МСР-1 как маркер, продуцируемый резидентными клетками. При изучении взаимосвязи МСР-1 в крови с клиническими показателями выявлена корреляция со значениями общего белка (Rs=–0,43; р&lt;0,05), эритроцитурией (Rs=–0,28;р&lt;0,05), а также с уровнем альбумина (Rs=–0,5; р&lt;0,05), что свидетельствует о роли МСР-1 в развитии именно нефритических форм гломерулонефритов. В зависимости от выраженности экспрессии МСР-1 в биоптатах встречаемость очагового тубулоинтерстициального фиброза (ТИФ) при экспрессии МСР-1, оцениваемой в 1 балл, составила 13,3 %, 2 балла – 14,3 %, 3 балла – 44,0 %. Выявленная достоверная корреляционная связь сывороточного уровня МСР-1 с выраженностью ТИФ подтверждает МСР-1-опосредованный механизм прогрессирования ХБП. ЗАКЛЮЧЕНИЕ. Продемонстрирована взаимосвязь сывороточной и тканевой форм МСР-1 с прогрессированием ТИФ при хроническом гломерулонефрите. MCP-1-индуцированная мезангиальная клетка играет решающую роль в развитии повреждения канальцев почек, а также его повышенная экспрессия связана с прогрессирующим тубулоинтерстициальным фиброзом и снижением почечной функции.</p></abstract><trans-abstract xml:lang="en"><p>BACKGROUND. To date, the study of the factors involved in the glomerular-tubular pathological connections leading to damage to the tubulointerstitial tissue is one of the topical areas of nephrology. THE AIM: to study the effect of MCP-1 in the development of tubulointerstitial fibrosis as a factor in the irreversible progression of chronic renal failure. PATIENTS ANDMETHODS. Prospective observation and retrospective analysis of case histories were carried out, which included a total of 75 patients with primary chronic glomerulonephritis. RESULTS. The average age of the patients was 36.7 ± 12.3 years, of which 52 were males, 23 were women. The average length of service in a nephrological disease was 3.0 [1.0; 5.0] years. The calculated GFR values are 87.3 ± 31.2 ml / min / 1.73 m2. In the general population, the moderate degree of MCP-1 expression, estimated at 2 points, was 35 %, pronounced expression was found in 25 % of the respondents. In the mesangium of the glomeruli and in macrophages, the expressed degree of MCP-1 expression was 20 % and 16 %, respectively, which characterizes MCP-1 as a marker produced by resident cells. When studying the relationship of MCP-1 in blood with clinical parameters, a correlation was found with the values of total protein (Rs= –0.43; p &lt;0.05), with erythrocyturia (Rs= –0.28; p &lt;0.05), as well as with an albumin level (Rs= –0.5; p &lt;0.05), which indicates the role of MCP-1 in the development of nephritic forms of glomerulonephritis. Depending on the severity of MCP-1 expression in biopsy specimens, the incidence of focal tubulointerstitial fibrosis with MCP-1 expression estimated at 1 point was 13.3 %, 2 points – 14.3 %, 3 points – 44.0 %. The revealed significant correlation between the serum level of MCP-1 and the severity of tubulointerstitial fibrosis confirms the MCP-1-mediated mechanism of progression of CKD. CONCLUSION. The relationship of serum and tissue forms of MCP-1 with the progression of tubulointerstitial fibrosis in chronic glomerulonephritis has been demonstrated. MCP-1-induced mesangial cell plays a critical role in the development of renal tubular damage, and its increased expression is associated with progressive tubulointerstitial fibrosis and decreased renal function.</p></trans-abstract><kwd-group xml:lang="ru"><kwd>тубулоинтерстициальный фиброз</kwd><kwd>моноцитарный хемоаттрактантный протеин-1</kwd><kwd>первичные гломерулонефриты</kwd><kwd>хроническая болезнь почек</kwd></kwd-group><kwd-group xml:lang="en"><kwd>tubulointerstitial fibrosis</kwd><kwd>monocytic chemoattractant protein-1</kwd><kwd>primary glomerulonephritis</kwd><kwd>chronic kidney disease</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Шилов ЕМ, Котенко ОН, Шилова ММ и др. Состояние нефрологической службы: заместительная почечная терапия в Российской Федерации в период с 2015 по 2019 г. Клиническая Нефрология 2020; 1: 6–14. doi: https://dx.doi.org/10.18565/nephrology.2020.1.6-14</mixed-citation><mixed-citation xml:lang="en">Shilov EM, Kotenko ON, Shilova MM and others. The state of the nephrological service: renal replacement therapy in the Russian Federation in the period from 2015 to 2019. Clinical Nephrology2020; 1: 6–14 (In Russ.)</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Milchakov KS, Shilov EM, Shvetzov MYu et al. Management of chronic kidney disease in the Russian Federation: A critical review of prevalence and preventive programmes. International Journal of Healthcare Management 2019; 12(4):322–326. doi: 10.1080/20479700.2018.1453970</mixed-citation><mixed-citation xml:lang="en">Milchakov KS, Shilov EM, Shvetzov MYu et al. Management of chronic kidney disease in the Russian Federation: A critical review of prevalence and preventive programmes. International Journal of Healthcare Management 2019; 12(4):322–326. doi: 10.1080/20479700.2018.1453970</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Kramer A, Pippias M, Noordzij M et al. The European Renal Association – European Dialysis and Transplant Association (ERAEDTA) Registry Annual Report 2015: a summary. Clin Kidney J 2018;11(1):108–122. doi:10.1093/ckj/sfx149</mixed-citation><mixed-citation xml:lang="en">Kramer A, Pippias M, Noordzij M et al. The European Renal Association – European Dialysis and Transplant Association (ERAEDTA) Registry Annual Report 2015: a summary. Clin Kidney J 2018;11(1):108–122. doi:10.1093/ckj/sfx149</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Хроническая болезнь почек (ХБП). Клинические рекомендации. N18.1/N18.2/N18.3/N18.4/N18.5/N18.9. М. 2021:233; https://cr.minzdrav.gov.ru/recomend/469_2</mixed-citation><mixed-citation xml:lang="en">Chronic Kidney Disease (CKD). Clinical guideline. N18.1/N18.2/N18.3/N18.4/N18.5/N18.9. M., 2021:233 https://cr.minzdrav.gov.ru/recomend/469_2</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Proudfoot AE. Chemokines and Glycosaminoglycans. Front Immunol 2015;26(6):246. doi: 10.3389/fimmu.2015.00246</mixed-citation><mixed-citation xml:lang="en">Proudfoot AE. Chemokines and Glycosaminoglycans. Front Immunol 2015;26(6):246. doi: 10.3389/fimmu.2015.00246</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Москалев АВ, Рудой АС, Апчел ВЯ. Хемокины, их рецепторы и особенности развития иммунного ответа. Вестник Военно-медицинской академии 2017; 2(58): 182–187</mixed-citation><mixed-citation xml:lang="en">Moskalev AV, Rudoy AS, Apchel VYa. Chemokines, their receptors and features of the development of the immune response. Bulletin of the Military Medical Academy 2017; 2 (58): 182–187. (In Russ.)</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Батюшин ММ, Гадаборшева ХЗ. Моноцитарный хемоаттрактантный протеин-1: роль в развитии тубулоинтерстициального фиброза при нефропатиях. Медицинский вестник Северного Кавказа 2017;2:234–239. doi:https://doi/org/10.14300/mnnc/2017/12067</mixed-citation><mixed-citation xml:lang="en">Batyushin MM, Gadaborsheva HZ. Monocytic chemoattractant protein-1: a role in the development of tubulointerstitial fibrosis in nephropathies. Medical Bulletin of the North Caucasus 2017; 2: 234–239. (In Russ.)</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Gao J, Liu X, Wei L et al. Genetic variants of MCP-1 and CCR2 genes and IgA nephropathy risk. Oncotarget 2016;7(47):77950–77957. doi: 10.18632/oncotarget.12847</mixed-citation><mixed-citation xml:lang="en">Gao J, Liu X, Wei L et al. Genetic variants of MCP-1 and CCR2 genes and IgA nephropathy risk. Oncotarget 2016;7(47):77950–77957. doi: 10.18632/oncotarget.12847</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Zhang J, Zhou R, Mi Y at al. Role of Human MesangialTubular Crosstalk in Secretory IgA-Induced IgA Nephropathy. Kidney Blood Press Res 2021;16:1–12. doi: 10.1159/000514183.</mixed-citation><mixed-citation xml:lang="en">Zhang J, Zhou R, Mi Y at al. Role of Human MesangialTubular Crosstalk in Secretory IgA-Induced IgA Nephropathy. Kidney Blood Press Res 2021;16:1–12. doi: 10.1159/000514183.</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Батюшин ММ, Гадаборшева ХЗ, Сарвилина ИВ и др. Взаимосвязь МСР-1 и тубулоинстерстициального фиброза при хроническом гломерулонефрите. Нефрология 2017; 21(5): 22–27. doi:10.24884/1561-6274-2017-21-5-22-27</mixed-citation><mixed-citation xml:lang="en">Batyushin MM, Gadaborsheva KhZ, Sarvilina IV et al. Relationship between MCP-1 and tubulointerstitial fibrosis in chronic glomerulonephritis. Nephrology 2017; 21 (5): 22–27. (In Russ.)</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Ahn YJ, Wang L, Asmis R. Quantification of Monocyte Chemotactic Activity In Vivo and Characterization of Blood Monocyte Derived Macrophages. J Vis Exp 2019; 12:150. http://dx.doi.org/10.3791/59706</mixed-citation><mixed-citation xml:lang="en">Ahn YJ, Wang L, Asmis R. Quantification of Monocyte Chemotactic Activity In Vivo and Characterization of Blood Monocyte Derived Macrophages. J Vis Exp 2019; 12:150. http://dx.doi.org/10.3791/59706</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Левицкая ЕС, Батюшин ММ, Пасечник ДГ и др. Прогнозирование ремоделирования ткани почек с учетом структурных изменений почечных артерий малого диаметра. Нефрология 2016;5:55–61</mixed-citation><mixed-citation xml:lang="en">Levitskaya ES, Batyushin MM, Pasechnik DG et al. Prediction of renal tissue remodeling taking into account structural changes in renal arteries of small diameter. Nephrology 2016; 5: 55–61. (In Russ.)</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Haller H, Bertram A, Nadrowitz F et al. Monocyte chemoattractant protein-1 and the kidney. Curr Opin Nephrol Hypertens 2016;25(1):42–49. doi: 10.1097/MNH.0000000000000186</mixed-citation><mixed-citation xml:lang="en">Haller H, Bertram A, Nadrowitz F et al. Monocyte chemoattractant protein-1 and the kidney. Curr Opin Nephrol Hypertens 2016;25(1):42–49. doi: 10.1097/MNH.0000000000000186</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Worawichawonga S, Worawichawongb P, Radinahameda D et al. Urine Epidermal Growth Factor, Monocyte Chemoattractant Protein-1 or Their Ratio as Biomarkers for Interstitial Fibrosis and Tubular Atrophy in Primary Glomerulonephritis. Kidney Blood Press Res 2016;41:997–1007. http://dx.doi.org/10.1159/000452595</mixed-citation><mixed-citation xml:lang="en">Worawichawonga S, Worawichawongb P, Radinahameda D et al. Urine Epidermal Growth Factor, Monocyte Chemoattractant Protein-1 or Their Ratio as Biomarkers for Interstitial Fibrosis and Tubular Atrophy in Primary Glomerulonephritis. Kidney Blood Press Res 2016;41:997–1007. http://dx.doi.org/10.1159/000452595</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Батюшин ММ, Броновицкая НА, Гасанов МЗ и др. Протеомный спектр мочи при нефропатиях различного генеза. Клиническая Нефрология 2014;1:50–54</mixed-citation><mixed-citation xml:lang="en">Batyushin MM, Bronovitskaya NA, Gasanov MZ et al. Proteomic spectrum of urine in nephropathies of various origins. Clinical Nephrology 2014; 1: 50–54 (In Russ.)</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
